Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)
Clinical Genitourinary Cancer · 2026
DOI: 10.1016/j.clgc.2025.102484 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Genitourinary Cancer, 2026. Verfasst von Audreylie Lemelin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Integrated health and social services centre of Chaudiere-Appalaches, Quebec, Canada. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: Attrition rates for patients with mRCC are not well characterized in the era of immunoncology (IO)-based combinations. This study aims to quantify real-world attrition rates by line of therapy, analyze associated clinical predictors, and describe treatment sequencing across multiple international centers. METHODS: IMDC data for patients with mRCC who received first line Nivolumab + Ipilimumab (IO-IO) or IO- Vascular Endothelial Growth Factor receptor targeted therapy (VEGFR TT) (IO-VE) were included. Clinical and pathologic characteristics and outcomes were extracted. Chi-square tests were used to compare categorical variables between patients who received second line and those who did not. A logistic regression model was used to assess predictors of second line therapy initiation. RESULTS: A total of 1411 patients were identified, of whom 995 patients were treated with first line IO-IO and 434 with IO-VE. Of them, 935 (704 first line IO-IO and 231 first line IO-VE) stopped first line and were suitable for second line therapy. Reasons for stopping first line included progressive disease (PD) in 41.1%, toxicity in 24.4%, death in 3.9%, complete response in 1.5% and other in 28.3%. Among second line suitable patients, 544 (58.2%) started any second line whereas 391 (41.8%) did not. Patients who stopped first line for PD were more likely to initiate second line than those who stopped for other reasons (57.9% vs. 17.6%, P < .00001). Patients who received second line were more likely to have clear-cell histology (77.2% vs. 66.8%, P = .04), without sarcomatoid features (57.2 vs. 44.8%, P = .02), a Karnofsky performance score (KPS) of 80 or higher (80.1 vs. 73.9%, P = .01), and bone metastases (39.0 vs. 28.1%, P = .0009). (Table 2). After adjusting for IMDC criteria, only age and reason for stopping first line remained significant predictors of receiving second line therapy. Among 353 patients who stopped second line, 199 (56.4%, overall 21.3%) started third line therapy. Of the 139 patients who stopped third line, 80 (57.6%, overall 8.6%) started fourth line therapy. CONCLUSIONS: In this real-world analysis, we found that just over half of suitable patients received the subsequent line of therapy post first line. We were able to identify age and reason for stopping first line as predictors of second line therapy initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Integrated health and social services centre of Chaudiere-Appalaches, Quebec, Canada.
- Arthur J.E. Child Comprehensive Cancer Center, University of Calgary, Calgary, Alberta, Canada. Electronic address: martin.zarba@albertahealthservices.ca.
- Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan.
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
- Genitourinary Oncology department, Dana-Farber Cancer Institute, Boston, MA.
- Department of Regional Helath Research, Southern Denmark University Hospital, Esbjerg, Denmark.
Zitieren
APA
Lemelin, A., Zarba, M., Takemura, K., Wells, J. C., Chehade, R. E. H., Donskov, F., Porta, C., De Velasco, G., Davis, I. D., Wood, L. A., Pal, S. K., Hansen, A. R., Tran, B., Bjarnason, G. A., Li, H., Kanesvaran, R., Powles, T., McKay, R. R., Choueiri, T. K., & Heng, D. Y. C. (2026). Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC). Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2025.102484
Vancouver
Lemelin A, Zarba M, Takemura K, Wells JC, Chehade REH, Donskov F, et al. Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC). Clinical Genitourinary Cancer. 2026. doi:10.1016/j.clgc.2025.102484
BibTeX
@article{Lemelin2026,
author = {Lemelin, Audreylie and Zarba, Martin and Takemura, Kosuke and Wells, J Connor and Chehade, Razane El Hajj and Donskov, Frede and Porta, Camillo and De Velasco, Guillermo and Davis, Ian D and Wood, Lori A and Pal, Sumanta K and Hansen, Aaron R and Tran, Ben and Bjarnason, Georg A and Li, Haoran and Kanesvaran, Ravindran and Powles, Thomas and McKay, Rana R and Choueiri, Toni K and Heng, Daniel Y C},
title = {Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)},
journal = {Clinical Genitourinary Cancer},
year = {2026},
doi = {10.1016/j.clgc.2025.102484}
}
EUVIMED